Answer
TAKHZYRO (lanadelumab) is used for routine prevention of recurrent hereditary angioedema (HAE) attacks in patients aged 2 years and older.
Sources for this answer
- TAKHZYRO 300 mg solution for injection in pre-filled syringeTakeda UK Ltd · emc · SmPC §4.1 Therapeutic Indications · Version 8Document updated
Sources checked